The proliferation of MC/9 cells treated with increasing concentrations of mGM-CSF was assessed. After 48 hour treatment with mGM-CSF, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.
The purity of recombinant mGM-CSF was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mGM-CSF and staining overnight with Coomassie Blue.
Western blot analysis of extracts from MC/9 cells untreated or treated with mGM-CSF for 10 minutes, using Phospho-Stat5 (Tyr694) (C11C5) Rabbit mAb #9359 (upper) and Stat5 (3H7) Rabbit mAb #9358 (lower).
With carrier: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2 containing 20 μg BSA per 1 μg mGM-CSF. Carrier free: Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.2.
Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles.Maintain sterility. Storage at -20°C should be in a manual defrost freezer.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mGM-CSF. All lots are greater than 98% pure.
Less than 0.01 ng endotoxin/1μg mGM-CSF.
The bioactivity of recombinant mGM-CSF was determined in a MC/9 cell proliferation assay. The ED50 of each lot is between 6-25 pg/ml.
Recombinant mGM-CSF contains no "tags" and the nonglycosylated protein has a calculated MW of 14,112.1. DTT-reduced protein migrates as a 22 kDa polypeptide and non-reduced protein migrates as a 19 kDa polypeptide due to intramolecular cystines. Lower mobility and heterogeneity in SDS-PAGE are due to glycosylation. The expected amino-terminal APTRS of recombinant mGM-CSF was verified by amino acid sequencing.
Recombinant mouse GM-CSF (mGM-CSF) Ala18-Lys141 (Accession #NP_034099) was expressed in human 293 cells at Cell Signaling Technology.
GM-CSF is produced by activated T cells, NK cells and macrophages (1,2). Target cells include granulocytes, monocyte precursors and subsets of differentiated myeloid cells (1,3,4). Many target cells require GM-CSF for survival. GM-CSF induces proliferation, is involved in the hematopoietic differentiation of dendritic cells and is a key factor in differentiation pathways leading from stem cells. GM-CSF activates effector functions of myeloid cells, thereby linking adaptive and innate immunity and in turn may boost anti-tumor immunity (5). GM-CSF receptor is composed of GM-CSFRα and the common β chain, βC, which is also utilized by IL-3 and IL-5 (1). Binding of GM-CSF initiates the Jak2, Stat5 and PI3K/Akt pathways (1).
Explore pathways + proteins related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.